•   
  • $0.00 USD
    0

Webinars

The following complimentary webcasts are scheduled. Please register to participate:

Please be aware that webinars are hosted through GoToWebinar. If you are not already set up to view webinars through this service, please allow 5 minutes before the start to establish access.


NGS Webinar

Automating Immunohistochemistry Standardization in your Laboratory

Date: July-9-2015
Time: 10:00am EDT / 3:00pm BST

Tissue-based immunohistochemical (IHC) data are important and variability in staining quality has a major impact on data quality. Sometimes this is the only type of data available to support critical decisions in research, business, or diagnostics. Although that should be reason enough to care a great deal about data quality, often this seems to be an area with room for improvement. 

In a case study BRAF V600E (Run 37) with the Canadian Immunohistochemistry Quality Control (cIQc), participating laboratories were asked to stain a colorectal carcinoma tissue microarray enriched for MLH1-deficient cases. Additionally, the slides stained by the participating laboratories also contained BRAF V600E genetically defined IHC Reference Standard cell lines provided by Horizon Diagnostics. Image analysis was used to quantify the staining quality and compared to the assessor panel, with excellent results. Using the same analysis algorithms it was possible to reproduce the same correlation to the assessor panel, demonstrating the possibility of using genetically defined cell lines with automated image analysis to assess laboratory staining quality. 

Key Topics

  • A case study highlighting variability in BRAF V600E IHC staining in a Proficiency testing Scheme 
  • Improving the consistency of IHC staining and quantitative assessment (QDP): 
  • Discuss providing quantitative analysis of EML4-ALK, ROS1, RET and EGFR reference standards 

Register

 


NGS Webinar

Understanding and Controlling for Sample and Platform Biases in NGS Assays

Date: July-22-2015
Time: 11:00am EDT / 4:00pm BST

In this webinar we will focus on next generation sequencing and discuss: the effect of formalin treatment on molecular protocols and how it can be controlled, how to select the sequencing platform most appropriate for your sample, evaluation of whether structural variants are being detected by your assay and how Reference Standards can be used in each validation parameter. 

Key Topics

  • The effect of formalin treatment on molecular protocols and how it can be controlled
  • How to select the sequencing platform most appropriate for your samples
  • Evaluation of whether structural variants are being detected by your assay
  • How Reference Standards can be used in each validation parameter
Register

 


NGS Webinar

Blueprint to Blue Sky: Analysing the Challenges and Solutions for IHC Companion Diagnostics

Date: August-6-2015
Time: 10:00am EDT / 3:00pm BST

The world of biomarker research has changed dramatically over the last 20 years with targeted therapy fundamentally changing drug development practices; there are not only new biomarkers but there are also complex biomarkers such as PD-L1. The situation has moved to a matrix of therapeutics and companion diagnostics, rather than the direct 1:1 relationship of the past.
With all this complexity it is essential to ensure the accuracy of biomarker analysis, however, manual assessments of complex biomarker expressions have been associated with significant inter- and intra-reader variability. There are ways of reducing certain types of errors associated with biomarker assessment and studies have shown that quantitative image analysis may be the solution. Therefore an essential part of blue sky thinking is toward the development of HDx IHC Reference Standards and Quantitative Digital Pathology methods to deliver a strong scoring confidence.

In response to the challenges of comparability of companion diagnostics, a blueprint proposal was discussed at the FDA-AACR-ASCO Public workshop on March 24 2015. This blueprint proposal acts as a PD-L1 comparison study and here a few highlights of the valuable efforts will be discussed.

Key Topics

  • Analysis of the key challenges facing IHC companion diagnostics and solutions such as the ‘Blueprint Proposal’.
  • Blue sky thinking in the development of an IHC reference material including the assessment by Quantitative Digital Pathology.
  • Standardizing IHC staining evaluation using high-quality image analysis systems.

Register